Praxis Precision Medicines: Wells Fargo cuts target price to $343 from $362
PRAX•Wells Fargo cut its target price for Praxis Precision Medicines to $343 from $362.
Related News
Upstream Bio Q3 net loss widens 22% to $41.19 million
UPB•
Harvard Apparatus Regenerative Technology Q3 2026 diluted loss per share more than doubles to $0.58
HRGN•
Ovid Therapeutics presents OV329 epilepsy program, targets Phase 2 data in second half of 2027
OVID•
IIFL Finance says Blackstone to invest 50 billion rupees for about 16% stake
BX•
Autolus Therapeutics Q3 2026 net loss narrows 30% year over year to $55.09 million
AUTL•